Skip to search formSkip to main contentSkip to account menu

Velcade

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Amyloid diseases in man are caused by as many as 23 different pre-cursor proteins already described. Cardiologists predominantly… 
Highly Cited
2009
Highly Cited
2009
Abstract 131 Introduction. Autologous stem cell transplantation (ASCT) after cytoreductive induction is considered standard of… 
Highly Cited
2007
Highly Cited
2007
Introduction. ASCT is considered the standard of care for younger patients (pts) with MM. The benefit of ASCT is at least partly… 
Highly Cited
2006
Highly Cited
2006
Proteasome inhibition results in proapoptotic changes in cancer cells, which may make them more sensitive to immune effector… 
Highly Cited
2005
Highly Cited
2005
INTRODUCTION: A 2-arm Phase I/II trial was initiated to determine activity and toxicities of the VTD combination in patients with… 
Review
2005
Review
2005
Normal cellular functioning requires processing of proteins regulating cell cycle, growth, and apoptosis. The ubiquitin… 
2004
2004
Abstract Introduction: Bortezomib, a first in class proteasome inhibitor, has become a standard of care in the treatment of… 
Highly Cited
2004
Highly Cited
2004
The combination of thalidomide and dexamethasone (TD) has induced disease remission in 69% of 132 newly diagnosed patients with… 
Highly Cited
2003
Highly Cited
2003
Targeting the ubiquitin-proteasome pathway has emerged as a promising approach for treating cancer. Bortezomib (VELCADETM…